{"url_path":"/sec/tenx/8-k/2026-06-04/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/34956/0001193125-26-257400-index.html","accession_number":"0001193125-26-257400","cik":"0000034956","ticker":"TENX","issuer_name":"TENAX THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/34956/0001193125-26-257400-index.html","primary_entity_key":"0000034956","primary_entity_name":"TENAX THERAPEUTICS, INC."},"word_count":235,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Security Holders.\n\nOn June 2, 2026, Tenax Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The following proposals were voted upon at the Annual Meeting and the final voting results with respect to each such proposal are set forth below.\n\nProposal 1: Election of Directors\n\nThe Company’s stockholders elected each of the following individuals to the Company’s Board of Directors for a one-year term expiring in 2027, or until his or her successor is duly elected and qualified, by the votes indicated below.\n\n \n\nMembers\n  \nFor\n  \nWithheld\n  \nBroker Non-Votes\n\nJune Almenoff\n\n  \n17,362,177\n  \n214,449\n  \n3,742,678\n\nMichael Davidson\n\n  \n15,762,162\n  \n1,814,464\n  \n3,742,678\n\nDeclan Doogan\n\n  \n17,394,626\n  \n182,000\n  \n3,742,678\n\nChristopher T. Giordano\n\n  \n17,397,265\n  \n179,361\n  \n3,742,678\n\nRobyn M. Hunter\n\n  \n17,394,848\n  \n181,778\n  \n3,742,678\n\nGerald T. Proehl\n\n  \n17,393,189\n  \n183,437\n  \n3,742,678\n\nStuart Rich\n\n  \n17,397,413\n  \n179,213\n  \n3,742,678\n\nProposal 2: Auditor Ratification\n\nThe Company’s stockholders ratified the appointment of Cherry Bekaert LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 by the votes indicated below.\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non-Votes\n\n21,304,543\n \n3,688\n \n11,073\n \nNone\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate: June 4, 2026\n \nTenax Therapeutics, Inc.\n\n \n\n \nBy:\n \n\n/s/ Christopher T. Giordano\n\n \n\n \n\n \nChristopher T. Giordano\n\n \n\n \n\n \nPresident and Chief Executive Officer"}